You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live

4

7

Final

Mass. Movers

Traders cheer Biogen Idec’s MS drug sales

Last week, Standard & Poor’s raised its rating to “A-” from “BBB+” on Weston-based Biogen Idec.

Globe File Photo/2013

Last week, Standard & Poor’s raised its rating to “A-” from “BBB+” on Weston-based Biogen Idec.

Continue reading below

MarketWatch.com said sales of Biogen Idec Inc.’s newest multiple sclerosis treatment were “causing murmurs on Wall Street and lifting shares of the company” as traders noted a strong first two weeks of sales for Tecfidera. Analyst Michael Yee of RBC Capital Markets said second-week sales were 42 times first-week sales, far outpacing those for competing treatments. He cited “very high awareness with both physicians and patients” and a “strong combination of efficacy and safety.”

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com